Summary of AVITA Medical FY Conference Call Company Overview - **Company**: AVITA Medical (NasdaqCM:RCEL) - **Industry**: Acute wound care, specifically focused on hospital-based treatments for burns, surgical wounds, and traumatic wounds [2][3] Core Products - **RECELL**: Flagship product for acute wound care, evolving from a manual to an automated process (RECELL GO and RECELL GO mini) [4][5] - **Cohealyx**: Collagen dermal matrix that prepares the wound bed for grafting, offering quicker vascularization compared to competitors [5][6] - **PermeaDerm**: Temporary biosynthetic matrix that protects and allows observation of the wound during healing [6][7] Market Dynamics - **Target Market**: Approximately 200 accounts in the U.S. with a Total Addressable Market (TAM) of $3.5 billion, focusing on a strategic TAM of $1.3 billion [11] - **Market Penetration**: Currently less than 5% across the portfolio, with RECELL at about 15% penetration [11][12] - **International Expansion**: Efforts in Australia, Japan, and Europe, with recent attention due to a Swiss nightclub fire highlighting the need for better treatment options [12][13] Financial Performance - **Growth Rate**: Achieved 11% growth in the previous year despite challenges, with expectations for sequential growth throughout 2026 [14][15] - **CAGR**: Company has experienced a compound annual growth rate of close to 30% over the last five years [14] - **Cost Management**: Focus on cost discipline while aiming for revenue growth, with strategic reductions in the sales force [15][16] Reimbursement Challenges - **Reimbursement Dynamics**: Ongoing issues with reimbursement from CMS and MACs, with about 70%-80% recovery expected in the near term [30][35] - **Impact on Sales**: Delays in reimbursement have caused confusion and disruption, but clarity is expected to improve in the coming months [33][34] Strategic Focus - **Product Adoption**: Emphasis on increasing penetration in existing accounts and expanding usage among different types of wounds and physicians [40][61] - **Clinical Studies**: Ongoing post-market studies for Cohealyx and PermeaDerm, with results expected to support product adoption [7][13] - **Sales Strategy**: A clinically based sales team that acts as consultants to surgeons, enhancing familiarity with products [62][63] Economic Benefits - **Speed to Healing**: RECELL allows patients to heal and be discharged 36% sooner, providing economic advantages for hospitals [53][72] - **Cost Savings**: Transitioning from allograft to PermeaDerm can save hospitals significant costs, as highlighted by a physician's estimate of $500,000 in annual savings [87] Profitability Outlook - **Margin Expectations**: Cohealyx and PermeaDerm expected to have around 50% margins, while RECELL will maintain higher margins in the low 80s [92] - **Path to Profitability**: Anticipated growth trajectory suggests that profitability is on the horizon if current trends continue [93] Conclusion - **Future Outlook**: AVITA Medical is positioned for growth with a strong focus on execution and product adoption, expecting to discuss improved financial metrics throughout the year [97]

Core Insights - The company aims for progressive revenue growth in 2026, targeting revenue between $80 million and $85 million after a challenging 2025 [3][4][5] Financial Performance - The gross margin for 2025 was reported at 82.1%, with a forecast of 83% to 85% for 2026, driven by expected growth in RECELL products [1][6][7] - Revenue for 2025 was $71.6 million, including $17.6 million in Q4, with a stable growth outlook of 12% to 19% for 2026 [2][3] Operational Strategy - The company has focused on disciplined execution in cash management, headcount, and forecasting to enhance predictability and performance in 2026 [4][5] - A new $60 million credit facility was established to reset revenue and cash covenants, allowing for improved financial flexibility [6][15][16] Product Focus - The company is prioritizing its three-product platform, which includes RECELL, RECELL GO, Cohealyx, and PermeaDerm, aiming to increase utilization and adoption [12][17] - The commercialization of vitiligo has been deprioritized due to uncertain reimbursement conditions, with a focus on core product adoption instead [6][17] Sales and Market Strategy - The sales force has been restructured to focus on 200 key accounts, including burn centers and trauma centers, to drive growth in existing relationships [11][12] - The company is navigating reimbursement challenges, with updates on Medicare rates expected to improve the sales environment [9][10]

Core Insights - AVITA Medical, Inc. is a leading company in therapeutic acute wound care, focusing on innovative solutions for wound healing [3] Group 1: Company Participation - AVITA Medical management will participate in the TD Cowen 46th Annual Health Care Conference in Boston, MA, with Cary Vance as Interim CEO and David O'Toole as CFO [1] - A presentation and fireside chat is scheduled for March 4 at 8:10 a.m. Pacific Time / 11:10 a.m. Eastern Time, with a live and archived webcast available on the company's website [2] Group 2: Product Offerings - The company's flagship product, RECELL, is FDA-approved for treating thermal burn and trauma wounds, utilizing the patient's own skin to create Spray-On Skin™ for enhanced clinical outcomes [3] - In the U.S., AVITA Medical holds exclusive rights to manufacture and distribute PermeaDerm®, a biosynthetic wound matrix, and Cohealyx™, a collagen-based dermal matrix [3] Group 3: International Approvals - RECELL is approved for various applications in international markets, including thermal burn and trauma wounds, and has received CE mark in Europe, TGA registration in Australia, and PMDA approval in Japan [4]

Summary of AVITA Medical Conference Call Company Overview - **Company**: AVITA Medical (NasdaqCM:RCEL) - **Date of Call**: February 18, 2026 Key Points Financial Performance - **2025 Revenue**: $71.6 million, representing an 11% growth compared to the previous year [8] - **Q4 Revenue**: $17.6 million, showing stability with a slight increase from $17 million in Q3 [3] - **2026 Revenue Guidance**: Expected to be between $80 million and $85 million, indicating progressive quarter-over-quarter growth [3][8] - **Gross Profit Margin**: 82.1% for the year, with a slight decrease to 81% in Q4 due to inventory reserves and product mix impacts [8][10] - **Operating Expenses**: Reduced to a normalized range of $23-$24 million, with a focus on maintaining disciplined cost management [11][52] Strategic Focus - **Execution and Growth**: The company aims for disciplined execution and progressive revenue growth in 2026, focusing on understanding customer needs and improving forecasting accuracy [1][2] - **Sales Force Optimization**: The sales force has been restructured to focus on 200 key accounts, including 120+ burn centers and 50-60 level one trauma centers [4][5] - **Product Portfolio**: The company has three products—RECELL, Cohealyx, and PermeaDerm—each facing unique challenges in market adoption [5][18] Market Dynamics - **Reimbursement Challenges**: The company has made progress in resolving reimbursement issues, with six out of seven Medicare Administrative Contractors (MACs) having published their rates [6][7] - **Product Adoption**: Efforts are ongoing to increase the utilization of RECELL among existing physicians and expand its use to new cases and accounts [20][21] - **International Expansion**: The company is making inroads in international markets, including Japan and Australia, with plans for RECELL GO approval [26][27] Future Outlook - **Path to Profitability**: The company aims to achieve cash flow breakeven through revenue growth and disciplined operating expenses, without the need for additional equity funding in the near term [51][52] - **Focus on Vitiligo**: The commercial effort for vitiligo has been deprioritized due to uncertain reimbursement and low economic viability [54][55] - **Long-term Growth**: The company expects to return to a compound annual growth rate (CAGR) of 20%-30% in the coming years, with a focus on stabilizing operations and reducing distractions [12][62] Additional Insights - **Credit Facility**: A new credit facility with Perceptive Advisors has been established to reset revenue covenants, providing more flexibility for future growth [15][16] - **Market Positioning**: The company is focused on leveraging clinical data and physician relationships to enhance product adoption and compete against existing alternatives [46][48] - **Management's Commitment**: The management team is dedicated to growing the company independently and is not currently seeking acquisition opportunities [57] This summary encapsulates the key insights and strategic directions discussed during the AVITA Medical conference call, highlighting the company's financial performance, market strategies, and future growth plans.

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $17.6 million and full-year revenue of approximately $71.6 million, representing about 11% growth over 2024 [5][11] - Full-year gross margin was 82.1%, down from 85.8% in 2024, due to inventory reserves and product mix changes [12] - Fourth quarter gross margin was 81.2%, compared to 87.6% for the same period last year [13] Business Line Data and Key Metrics Changes - The focus for 2025 was on resolving reimbursement uncertainty for the RECELL product, with six of the seven Medicare Administrative Contractors publishing payment rates for RECELL procedures [6] - Approximately 90% of revenue comes from about 200 burn and trauma centers, with a shift towards organic monthly usage patterns rather than bulk ordering [6][7] Market Data and Key Metrics Changes - The company is taking a disciplined distributor-led approach to expand its footprint in select international markets, focusing on establishing familiarity and operational readiness [9] - Initial clinical use of RECELL GO in European markets has begun, with a focus on responding to urgent needs in the burn community [9] Company Strategy and Development Direction - The strategy is centered around a single integrated platform consisting of RECELL, Cohealyx, and PermeaDerm, aimed at increasing adoption and utilization among clinicians [7] - The company expects full-year revenue for 2026 to be between $80 million and $85 million, reflecting growth of approximately 12% to 19% over 2025 [10] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of establishing a disciplined operating model and improving visibility into cash use, which are expected to support consistent execution in 2026 [4][10] - The company aims to maintain disciplined control of operating costs while supporting revenue growth with a stable and scalable cost structure [17] Other Important Information - The company refinanced its debt through a new credit facility, which is designed to reduce covenant risk and support execution rather than constrain it [16] - The fourth quarter marked the third consecutive quarter of improvement in net cash use, declining from $10.1 million in Q2 to $5.1 million in Q4 [15] Q&A Session Summary Question: Guidance on revenue covenants and growth pace - Management clarified that the $15.4 million revenue covenant is not a guidance figure and indicated that they expect growth to be progressive from Q4 to Q1 and throughout the year [20][25] Question: Reimbursement dynamics affecting 2025 - Management confirmed that they are engaged with all seven MACs and are optimistic about the seventh MAC publishing payment rates soon, with no concerns about disruptions [30][31] Question: Customer experience with Cohealyx and PermeaDerm - Management discussed the process of working with champions in accounts to facilitate the adoption of Cohealyx and PermeaDerm, noting early positive experiences [37][38] Question: Drivers of growth for 2026 guidance - Management indicated that growth will be driven by increased utilization within existing accounts and contributions from all three product lines, including RECELL, Cohealyx, and PermeaDerm [49]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $17.6 million and full-year revenue of approximately $71.6 million, representing about 11% growth over 2024 [5][11] - Full year gross margin was 82.1%, down from 85.8% in 2024, reflecting inventory reserves and product mix changes [12] - Fourth quarter gross margin was 81.2%, compared to 87.6% for the same period last year [13] Business Line Data and Key Metrics Changes - Approximately 90% of revenue comes from about 200 burn and trauma centers, with a focus on increasing adoption and utilization of products like RECELL, Cohealyx, and PermeaDerm [6][7] - The Cohealyx I post-market study is fully enrolled, and the PermeaDerm I study is nearing full enrollment, with data expected later in 2026 [8] Market Data and Key Metrics Changes - Six of the seven Medicare administrative contractors have published payment rates for RECELL procedures, which is expected to restore confidence among clinicians [6] - The company is taking a disciplined distributor-led approach in select international markets, focusing on establishing operational readiness [9] Company Strategy and Development Direction - The company aims to drive disciplined execution, refine commercial focus, and position for growth in 2026, with a strategy centered around an integrated platform of products [4][10] - The company expects full year revenue of $80 million to $85 million in 2026, representing growth of approximately 12% to 19% over 2025 [10] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of predictable reimbursement for products and the need for increased adoption and utilization by clinicians [6][18] - The company is focused on maintaining disciplined control of operating costs and supporting revenue growth with a stable cost structure [17] Other Important Information - The company refinanced its debt through a new credit facility, which provides more flexibility and reduces covenant risk [15][16] - The fourth quarter marked the third consecutive quarter of improvement in net cash use, declining from $10.1 million in Q2 to $5.1 million in Q4 [15] Q&A Session Summary Question: Guidance on revenue covenants and growth pace - Management clarified that the $15.4 million covenant is not a guidance figure and that they expect growth to continue from Q4 into Q1 and throughout the year [20][21] Question: Reimbursement dynamics affecting 2025 - Management confirmed engagement with all seven MACs and expressed optimism about the seventh MAC publishing payment rates soon [30][31] Question: Customer experience with Cohealyx and PermeaDerm - Management discussed the process of working with champions in accounts to facilitate the adoption of Cohealyx and PermeaDerm, noting early positive experiences [37][38] Question: Drivers of growth for 2026 guidance - Management indicated that growth will come from increased utilization within existing accounts and contributions from Cohealyx and PermeaDerm [49]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $17.6 million and full-year revenue of approximately $71.6 million, representing about 11% growth over 2024 [5][12] - Full year gross margin was 82.1%, down from 85.8% in 2024, reflecting inventory reserves and product mix changes [12] - Fourth quarter gross margin was 81.2%, compared to 87.6% for the same period last year [13] - Total operating expenses in the fourth quarter were $24.7 million, down 5% year-over-year, primarily due to lower sales and marketing expenses [14] Business Line Data and Key Metrics Changes - The company focused on increasing adoption and utilization of its products, with approximately 90% of revenue coming from about 200 burn and trauma centers [6][8] - The Cohealyx I post-market study is fully enrolled, and the PermeaDerm I study is nearing full enrollment, with data expected later in 2026 [9] Market Data and Key Metrics Changes - Six of the seven Medicare administrative contractors have published payment rates for RECELL procedures, which has begun to restore confidence for clinicians [6] - The company is taking a disciplined distributor-led approach to build its footprint in select international markets [10] Company Strategy and Development Direction - The company aims to drive disciplined execution, refine commercial focus, and position itself for growth in 2026 [4] - The strategy is built around a single integrated platform of RECELL, Cohealyx, and PermeaDerm, used repeatedly by the same clinicians [8] - The company expects full year revenue of $80 million-$85 million in 2026, representing growth of approximately 12%-19% over 2025 [11] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of predictable reimbursement for products and clinicians to drive routine use of RECELL [6] - The company is focused on establishing the right operating cadence and executing fundamentals well to ensure consistent progress [8] - Management expressed confidence in the normalization of RECELL utilization and the expansion of portfolio use within core accounts [11] Other Important Information - The company refinanced its debt through a new credit facility, which provides more flexibility and reduces covenant risk [15][16] - The fourth quarter marked the third consecutive quarter of improvement in net cash use, declining to $5.1 million [15] Q&A Session Summary Question: Guidance on revenue growth pace - Management clarified that the $15.4 million revenue covenant is not a guidance figure and that they expect progressive growth from Q4 to Q1 and throughout the year [22][26] Question: Reimbursement dynamics affecting 2025 - Management confirmed that they are engaged with all seven MACs and are hopeful for the seventh MAC to publish payment rates soon [30][31] Question: Customer experience with Cohealyx and PermeaDerm - Management indicated that champions in accounts are helping to push Cohealyx and PermeaDerm through the VAC process, with early signs of uptake [37][38] Question: Drivers of growth for 2026 guidance - Management expects growth from all three product lines, primarily driven by increased utilization within existing accounts [48]

Core Insights - AVITA Medical reported financial results for Q4 and full year 2025, indicating a year of stabilization and a shift towards execution-focused growth in 2026 [1][4]. Fourth Quarter 2025 Financial Highlights - Total revenue for Q4 2025 was $17.6 million, a decrease of 4% from $18.4 million in Q4 2024, primarily due to reimbursement headwinds [6][7]. - Gross profit margin was 81.2%, down from 87.6% in Q4 2024, influenced by product mix and inventory adjustments [8]. - Operating expenses decreased by 5% to $24.7 million compared to $26.1 million in Q4 2024, reflecting a lower cost base [9]. - Net loss for Q4 2025 was $11.6 million, or a loss of $0.38 per share, compared to a loss of $11.6 million, or $0.44 per share in Q4 2024 [12]. Full-Year 2025 Financial Highlights - Total revenues for 2025 increased by 11% to $71.6 million from $64.3 million in 2024, driven by deeper penetration in customer accounts and new product launches [13]. - Gross profit margin for the full year was 82.1%, down from 85.8% in 2024, primarily due to product mix and higher inventory reserves [14]. - Total operating expenses for 2025 were $101.4 million, a decrease of 9% from $111.8 million in the prior year [15]. - Net loss for the full year was $48.6 million, or a loss of $1.74 per share, compared to a net loss of $61.8 million, or $2.39 per share in 2024 [16]. Business Updates and Future Guidance - The company expects full-year 2026 revenue in the range of $80 to $85 million, representing growth of approximately 12% to 19% compared to 2025 [5]. - In January 2026, the company refinanced its existing debt under a new credit facility with Perceptive Advisors, securing up to $60 million to strengthen its capital structure [17][18]. - As of January 2026, six of the seven Medicare Administrative Contractors have published payment rates for RECELL, alleviating a key constraint on utilization experienced in 2025 [6]. - The company is focused on disciplined cash management and accelerating commercial momentum across its core U.S. burn and trauma center opportunities [19].

Core Insights - AVITA Medical presented data from 19 scientific abstracts at the 2026 Boswick Burn & Wound Symposium, showcasing the integrated use of its technologies RECELL, PermeaDerm, and Cohealyx in wound care [1][2][3] Group 1: Integrated Use of Technologies - The first surgeon-reported experience integrating RECELL, PermeaDerm, and Cohealyx was highlighted, demonstrating reduced need for painful dressing changes and avoiding long-distance follow-ups [3] - This integrated approach is particularly beneficial for rural and community hospitals with limited access to specialized burn services [3] Group 2: Clinical Findings - Initial findings from multicenter clinical trials on PermeaDerm and Cohealyx were presented, with full results expected in 2026 [4] - PermeaDerm showed early blood vessel growth and organized tissue formation without increased inflammation compared to traditional human skin for temporary coverage [5] - Cohealyx demonstrated cellular infiltration and early blood vessel formation within two weeks, preparing the wound for skin grafting without complications [6] Group 3: RECELL Evidence and Benefits - A systematic review of 27 peer-reviewed studies reinforced the benefits of RECELL, showing consistent trends in healing, reduced complications, and shorter hospital stays [7][10] - In older burn patients, adding RECELL to standard skin grafting resulted in nearly 16 days shorter hospital stays and fewer graft failures [9] - Patients treated with RECELL for deep partial-thickness burns spent about one-third less time in the hospital compared to traditional grafting methods [9] Group 4: Practical Applications - Surgeons are demonstrating how the staged use of AVITA Medical's advanced wound care technologies can improve healing and help hospitals manage limited resources [11]

Summary of AVITA Medical FY Conference Call Company Overview - **Company**: AVITA Medical (NasdaqCM:RCEL) - **Industry**: Medical Technology, specifically focused on burn treatment and wound care Key Points and Arguments 1. **Mission and Focus**: AVITA Medical is dedicated to patient care, emphasizing clinical data, innovation, and economic benefits for customers [2][4] 2. **Market Opportunity**: There are approximately 40,000 hospitalized burn patients annually, with many not receiving optimal care. AVITA's Resell product line aims to address this gap [4] 3. **Product Line**: The company offers several products including RECELL, RECELL GO, RECELL Micro, CoHelix, and PermeaDerm, which are designed for wound closure and healing [5][6] 4. **Economic Benefits**: The use of AVITA's products can lead to significant cost savings for hospitals, including a potential reduction of up to $42,000 in costs due to a 36% reduction in length of stay [14][20] 5. **Growth Strategy**: The company aims to penetrate existing accounts more deeply, currently only achieving about 5% penetration across three products [10] 6. **International Expansion**: AVITA is expanding into Europe, Australia, and Japan, with recent events in Switzerland increasing product visibility [11] 7. **Reimbursement Challenges**: The company faces reimbursement uncertainties, particularly with the execution of Category I CPT codes, which has impacted growth [12][15] 8. **Financial Guidance**: AVITA has provided guidance for 2026, expecting revenue to grow from approximately $72 million in 2025 to between $80 million and $85 million [17][22] 9. **Debt Refinancing**: The company has refinanced its debt with more favorable terms, providing a buffer for cash management and operational focus [17][18] 10. **Clinical Studies**: Ongoing post-market studies for CoHelix and PermeaDerm are expected to yield data that will be shared throughout the year, contributing to clinical credibility [13][14] 11. **Sales Strategy**: The sales team is focused on existing accounts and building relationships with physicians to drive product adoption [20][29] 12. **Cash Management**: AVITA has improved its cash management practices, reducing cash burn and positioning itself for growth without significant additional spending [31][32] Additional Important Content - **Utilization as a KPI**: The company emphasizes tracking utilization rates of its products as a precursor to revenue growth, indicating a focus on operational metrics [33][34] - **Market Sentiment**: There is a strong positive sentiment among physicians regarding the RECELL product, which is seen as a gold standard in burn treatment [19] - **Execution Focus**: The leadership stresses the importance of execution and focus on core business areas to drive growth and operational efficiency [28][29]